Brief: Lee's Pharmaceutical Says Phase III Trial Of Staccato Loxapine Meets Primary Endpoint
03/09/2020 11:20
Sept 3 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* PHASE III TRIAL OF STACCATO LOXAPINE MET ITS PRIMARY
ENDPOINT
* NEW DRUG APPLICATION EXPECTED TO BE SUBMITTED BY END OF
2020
* UPDATES ON TRIAL OF STACCATO LOXAPINE FOR TREATMENT OF
AGITATION
ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
Source text for Eikon: ID:nHKS6cgvD5
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals